218 related articles for article (PubMed ID: 30584165)
1. Updating Our Definitions of Parkinson's Disease for a Molecular Age.
Chen-Plotkin AS; Zetterberg H
J Parkinsons Dis; 2018; 8(s1):S53-S57. PubMed ID: 30584165
[TBL] [Abstract][Full Text] [Related]
2. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia.
Compta Y; Parkkinen L; Kempster P; Selikhova M; Lashley T; Holton JL; Lees AJ; Revesz T
Neurodegener Dis; 2014; 13(2-3):154-6. PubMed ID: 24028925
[TBL] [Abstract][Full Text] [Related]
3. Candidate biomarkers for Parkinson's disease.
Khodadadian A; Hemmati-Dinarvand M; Kalantary-Charvadeh A; Ghobadi A; Mazaheri M
Biomed Pharmacother; 2018 Aug; 104():699-704. PubMed ID: 29803930
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease.
Fricova D; Harsanyiova J; Kralova Trancikova A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212934
[TBL] [Abstract][Full Text] [Related]
5. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
Vargas JY; Grudina C; Zurzolo C
Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
[TBL] [Abstract][Full Text] [Related]
6. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease biomarkers based on α-synuclein.
Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
9. Tears - more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease.
Edman MC; Janga SR; Kakan SS; Okamoto CT; Freire D; Feigenbaum D; Lew M; Hamm-Alvarez SF
Biomark Med; 2020 Feb; 14(2):151-163. PubMed ID: 32064896
[TBL] [Abstract][Full Text] [Related]
10. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
11. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions.
Walker L; Stefanis L; Attems J
J Neurochem; 2019 Sep; 150(5):467-474. PubMed ID: 30892688
[TBL] [Abstract][Full Text] [Related]
12. Where and how alpha-synuclein pathology spreads in Parkinson's disease.
Wakabayashi K
Neuropathology; 2020 Oct; 40(5):415-425. PubMed ID: 32750743
[TBL] [Abstract][Full Text] [Related]
13. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
He Y; Yu Z; Chen S
ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
[TBL] [Abstract][Full Text] [Related]
14. Salivary Biomarkers for Parkinson's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K; Owecki W; Jankowski J; Surdacka A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391952
[TBL] [Abstract][Full Text] [Related]
15. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
16. Evidence against a reliable staging system of alpha-synuclein pathology in Parkinson's disease.
Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RK
Neuropathol Appl Neurobiol; 2009 Feb; 35(1):125-6. PubMed ID: 19187066
[No Abstract] [Full Text] [Related]
17. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
[TBL] [Abstract][Full Text] [Related]
18. Post-translational modification of α-synuclein in Parkinson's disease.
Barrett PJ; Timothy Greenamyre J
Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
[TBL] [Abstract][Full Text] [Related]
19. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease.
Ma LY; Liu GL; Wang DX; Zhang MM; Kou WY; Feng T
ACS Chem Neurosci; 2019 Feb; 10(2):812-823. PubMed ID: 30714719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
